NewAmsterdam Pharma Announces Amended Employment Agreement for Chief Scientific Officer Dr. John Kastelein

Reuters
12 Jul
NewAmsterdam Pharma Announces Amended Employment Agreement for Chief Scientific Officer Dr. John Kastelein

NewAmsterdam Pharma Company NV has announced a new compensation agreement for Dr. John Kastelein, the company's Chief Scientific Officer and director. Effective from July 1, 2025, this amended and restated Employment Agreement replaces the previous one dated November 18, 2022. Under the new terms, if Dr. Kastelein's employment is terminated without cause, he will receive a severance package including 12 months of his base salary, any earned or payable bonuses, and a prorated bonus for the year of termination. Additionally, should his termination occur related to a change in control, his time-based stock options and equity awards will be accelerated, making them fully exercisable or nonforfeitable, with an extended exercise period for certain options. These changes reflect significant enhancements to Dr. Kastelein's compensation and benefits package.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-158211), on July 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10